IntelGenx responds to rejection of migraine film

This Week

Oct 26, 2022

BD joins Biocorp's roster of smart injectable delivery partners

FDA accepts ARS’ filing for approval of nasal spray EpiPen rival for review

After back-to-back rejections, IntelGenx shares data on migraine film formulation with FDA

VectorBuilder bags $57M to build out gene delivery capabilities

The Top Line Podcast: don’t miss out on the newest episode where we discuss ASCO data, rising health tech stars, and more. Listen now.

 

Featured

BD joins Biocorp's roster of smart injectable delivery partners

Biocorp’s business development team is keeping the pedal to the metal. Days after disclosing news of its deal with Merck KGaA, the delivery systems player revealed a pact with BD to use connected technology to track adherence for self-administered injectable drugs.
 

Top Stories

FDA accepts ARS’ filing for approval of nasal spray EpiPen rival for review

ARS Pharmaceuticals has taken a step toward FDA approval of its epinephrine nasal spray. Seeking to challenge EpiPen, the San Diego-based company has had its application for approval accepted and put itself on track to learn its fate around the middle of next year.

After back-to-back rejections, IntelGenx shares data on migraine film formulation with FDA

Thirty months after being knocked back by the FDA, IntelGenx has filed its response to the complete response letter to advance its push to bring its oral disintegrating film migraine drug to the U.S. market.

VectorBuilder bags $57M to build out gene delivery capabilities

VectorBuilder Biotechnology has secured investor backing for its push to support gene delivery, raising a 410 million Chinese yuan ($57 million) series C financing round to upgrade and expand its R&D and manufacturing capabilities.

J&J sets sights on $60B in pharma sales by 2025, targets 8 brands to deliver growth

With $13.2 billion in pharma sales this quarter, $60 billion in pharma sales by 2025 might seem like a lofty goal. But the company is standing by the projection, citing eight key brands during its third-quarter earnings conference call.
 
Fierce podcasts

Don't miss an episode

'The Top Line': Pfizer's kickback lawsuit, top vaccine companies

This week on "The Top Line," we talk about our special report on the top 10 vaccine company rankings. We also report the news on Pfizer's kickback lawsuit, OTC hearing aids and more.

 

Resources

eBook

Optimize Digital Engagement Across the Patient Journey

Improve patient engagement, adherence, and outcomes
eBook

How the Cloud Puts Precision Medicine Within Reach for Startups

In this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities.

Whitepaper

EHR vs Registry Data for RWE – Heart Failure as a Case Study

Electronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs?
eBook

The Essential Components of a Successful Remote Patient Monitoring Program

Looking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs.
Whitepaper

Navigating the Data Deluge: Turning Data Into Insight Across the Health Care and Life Sciences Industries

Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem.

eBook

Optimize the value and impact of your real-world data

With real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy.
Whitepaper

Commercializing Gene Therapies, Part I - Introduction

This paper is the first in a 4-part series focused on developing commercial models for gene therapies
Whitepaper

A Guide to Pre-Validated Software-as-a-Service LIMS

SaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security.
Whitepaper

The Most Suitable Dosage Form Technologies for the Oral Delivery of Lipid-Based Formulations

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?
Research

Versatility of Softgel Technology - Encapsulation of a Volatile Compound

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.
Whitepaper

Lipid-Based Drug Delivery System to Bring Poorly Soluble Drugs to Market

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?
Webinar

The Faster Path From Pre-Filled Syringe to Auto-Injector

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.

Whitepaper

Formulation Strategies When Transitioning From Vial to PFS

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Whitepaper

Softgel Formulation Enables Oral Delivery of Testosterone

Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy.

Whitepaper

Strategies for the Optimal Scale-up & Tech Transfer of Oral Small Molecules

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.